

ENQUETE HEMOPATHIES MALIGNES

Février-Juillet 2015

Magali BALHADERE

Attachée de Recherche Clinique

Dr Olivier FITOUSSI


Polyclinique Bordeaux Nord

Participation : 15 centres

Agen
Albi
Bordeaux
Caen
Chambéry
Clermont Ferrand
Le Mans
Lyon
Montluçon
Montpellier
Mougins
Nîmes
Pau
Strasbourg
Toulouse




- ✓ 869 fiches recueillies sur 6 mois
- ✓ 36 nouveaux cas enregistrés par semaine
- ✓ 10% des fiches comportent des données manquantes lors de l'analyse finale




LES GRANDES LIGNES





Nombre de Nouveaux Cas sur 6 mois



HLA diagnostique environ 5 % des hémopathies malignes en France




Les 6 principales hémopathies malignes :


- ✓ LLC
- ✓ LNH indolents
- ✓ Myélome multiple
- ✓ LNH de haut grade
- ✓ Myélodysplasies
- ✓ LNH de type folliculaire

Incidence annuelle des hémopathies en France


LLC	4500
LNH indolents	4000
myélome multiple	4900
LNH de haut grade	8000
myélodysplasie	4000
LNH de type folliculaire	2500
thrombocyttémie essentielle	1000
maladie de Hodgkin	1800
maladie de Vaquez	1000
LMC	800
LNH du manteau	650
myélofibrose primitive	400

Répartition des Hémopathies





Toutes hémopathies confondues




➔ Majorité de patients de + 75 ans pour :


- ✓ *Myélodysplasies*
- ✓ *Maladie de Vaquez*
- ✓ *Myélofibrose primitive*

Patients âgés de plus de 75 ans


Selon le type d'hémopathie




Traitement versus Surveillance




- surveillance
- traitement (RT compris)





Patients Autogreffés en 1^{ère} Intention Thérapeutique




ANALYSE EN DETAILS DES 6 HEMOPATHIES PRINCIPALES





LA LLC






■ stade A


■ stade B

■ stade C


Facteurs Pronostiques de la LLC






résultat des facteurs pronostiques




anomalies observées








Suivi de la MRD




■ suivi MRD


■ pas de suivi MRD

LNH INDOLENTS







Différents Types de LNH indolents




- LNH de la zone marginale
- LNH de type Waldenstrom
- LNH de type malt
- LNH de type lymphocytaire
- leucémie à tricholeucocytes
- autre
- leucémie à prolymphocytes








Traitement par Radiothérapie en 1^{ère} Intention




LE MYELOME MULTIPLE










résultats des facteurs pronostiques




anomalies observées












Traitement par radiothérapie en 1^{ère} Intention








LNH DE HAUT GRADE












Traitement versus Surveillance

- surveillance
- traitement








Traitement par Radiothérapie en 1^{ère} Intention




MYELOYDYSPLASIES










Traitement versus Surveillance







LNH DE TYPE FOLLICULAIRE









Traitement versus Surveillance






Traitement d'Entretien




- entretien
- pas d'entretien


Traitement par Radiothérapie en 1^{ère} Intention

LMC ET MYÉLOFIBROSE PRIMITIVE (PARENTHÈSE NOVARTIS)




Traitement de 1^{ère} Intention de la LMC

Traitement vs surveillance




- surveillance
- traitement

traitement de 1ère intention




- Hydréa
- allogreffe
- Jakavi

LA RECHERCHE CLINIQUE




Proposition d'un Essai Thérapeutique Toutes Hémopathies Confondues




- proposition d'un essai thérapeutique
- patients recevant un traitement standard


Proposition d'un Essai Thérapeutique




LLC




LNH indolents




Myélodysplasies



LNH de haut grade



Myélome multiple



LNH folliculaire

Commentaires



Succès du groupe HLA !

- ✓ Projet commun
- ✓ Réalisation pragmatique (effet libéral ?)

Remerciements

- ✓ Magali
- ✓ Docteurs
- ✓ Novartis

- **Que faire de ces données ?**
 - ✓ Protégées ou libre d'accès
 - ✓ INCA
 - ✓ Posters, publications

- **Discussions**
 - ✓ Industriels (phase II; Observatoire)
 - ✓ Tutelles (ARS)
 - ✓ Sociétés savantes

www.hematolib.fr

